Belpointe Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.5M Sell
13,616
-2,066
-13% -$200K 0.04% 399
2026
Q2
$1.23M Buy
15,682
+594
+4% +$40.5K 0.04% 429
2026
Q1
$975K Buy
15,088
+7,123
+89% +$502K 0.04% 461
2025
Q4
$536K Buy
7,965
+3,677
+86% +$247K 0.02% 631
2025
Q3
$314K Buy
+4,288
New +$285K 0.01% 780
2024
Q4
– Sell
-4,403
Closed -$252K – 904
2024
Q3
$252K Buy
4,403
+526
+14% +$30.2K 0.02% 723
2024
Q2
$203K Buy
+3,877
New +$170K 0.01% 729
2023
Q2
– Sell
-1,238
Closed -$47.3K – 1721
2023
Q1
$47.3K Buy
1,238
+366
+42% +$17.2K ﹤0.01% 1736
2022
Q4
$49.6K Buy
+872
New +$44.6K ﹤0.01% 1619

Other funds holding HALO

Belpointe Asset Management's HALO Position: Q3 2026 in Review

Belpointe Asset Management reduced its Halozyme (HALO) stake by 13% in Q3 2026, selling an estimated $200K and leaving 13,616 shares worth $1.5M. The position accounts for 0.04% of the portfolio, ranked #399.

Belpointe Asset Management first reported a position in HALO in Q4 2022 and has held it in 9 quarters since. 636 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Belpointe Asset Management held 13,616 shares of Halozyme worth $1.5M as of Q3 2026.
  • Belpointe Asset Management sold 2,066 Halozyme shares in Q3 2026, an estimated $200K.
  • Halozyme made up 0.04% of Belpointe Asset Management's portfolio in Q3 2026, its #399 holding.
  • Belpointe Asset Management first reported a position in Halozyme in Q4 2022 and has held it in 9 quarters since.
  • 636 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Belpointe Asset Management's 13F filing for Q3 2026, filed 9 Nov 2026.